ArticleProceedings of the National Academy of Sciences of the United States of America2017
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- The Association of EGFL7 Polymorphism and Expression with Cervical Cancer Susceptibility and Pathogenesis.International journal of general medicine · 2026Article
- PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression.Cancer cell international · 2023Review
- Relation among EGFL7, ITGB3, and KLF2 and their clinical implication in multiple myeloma patients: a prospective study.Irish journal of medical science · 2022Article
- EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome.Journal of pathology and translational medicine · 2022Article
- Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- The Polymorphism and Expression of EGFL7 and miR-126 Are Associated With NSCLC Susceptibility.Frontiers in oncology · 2022Article
- Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of theHaematologica · 2021Article
- LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL.Biomarker research · 2021Article
- Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.International journal of molecular sciences · 2021Review
- Diagnostic Utility of IGF2BP1 and Its Targets as Potential Biomarkers in ETV6-RUNX1 Positive B-Cell Acute Lymphoblastic Leukemia.Frontiers in oncology · 2021Article
- State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia.Cancer research · 2020Article
- MG53 Does Not Manifest the Development of Diabetes inDiabetes · 2020Article
- The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models.Blood advances · 2020Article
- Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin.Frontiers in oncology · 2020Article
- Article
- The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.Leukemia · 2019Article
- Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes.Cancer medicine · 2019Article
- Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.Leukemia · 2019Article
- EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.Oncogene · 2019Article
- microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor Mediated by Its Host Gene EGFL7.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 1 country.
Dimitrios PapaioannouThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Changxian ShenThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Betina McNeilThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Marius BillThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Malith KarunasiriThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Matthew H BurkeThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Hatice Gulcin OzerDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH 43210.
Selen A YilmazDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH 43210.
Nina ZitzerThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Gregory K BehbehaniThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Christopher C OakesThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Damian J SteinerThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Guido MarcucciGehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010.
Bayard L PowellDepartment of Internal Medicine, The Comprehensive Cancer Center of Wake Forest University, Wake Forest University, Winston-Salem, NC 27157.
Jonathan E KolitzHofstra North Shore-Long Island Jewish School of Medicine, Lake Success, NY 11042.
Thomas H CarterHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242.
Eunice S WangDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Carlo M CroceDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210 carlo.croce@osumc.edu adrienne.dorrance@osumc.edu.
Michael A CaligiuriThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Ramiro GarzonThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Adrienne M DorranceThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; carlo.croce@osumc.edu adrienne.dorrance@osumc.edu.
The Ohio State University · USCity of Hope · USRoswell Park Comprehensive Cancer Center · USUniversity of Iowa · USWake Forest University · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MCancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4MCancer and Leukemia Group B - The Ohio State UniversityU10CA077658 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 1998 to 2013
$6.0MPHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AMLR01CA102031 · NCI · OHIO STATE UNIVERSITY · PI GUZMAN, MONICA L, MARCUCCI, GUIDO · 2004 to 2017
$3.8MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA102031NCI NIH HHS R01 CA135332NCI NIH HHS R35 CA197706NCI NIH HHS R35 CA197734NCI NIH HHS U10 CA077658NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180861NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171
Abstract
Epithelial growth factor-like 7 (EGFL7) is a protein that is secreted by endothelial cells and plays an important role in angiogenesis. Although EGFL7 is aberrantly overexpressed in solid tumors, its role in leukemia has not been evaluated. Here, we report that levels of both
Indexed as
AdultAgedAged, 80 and overAge FactorsAngiogenic ProteinsAnimalsAntibodies, BlockingCalcium-Binding ProteinsCase-Control StudiesCell Line, TumorCell ProliferationDisease-Free SurvivalEGF Family of ProteinsEndothelial Growth FactorsFemaleHumansAngiogenic ProteinsAntibodies, BlockingCalcium-Binding ProteinsEGF Family of ProteinsEGFL7 protein, humanEgfl7 protein, mouseEndothelial Growth FactorsMicroRNAsMIRN126 microRNA, humanProteinsRecombinant ProteinsRNA, Messengeracute myeloid leukemiaclinical outcomeEGFL7
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.